Protocol Title: Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vederin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812)

Target Population: Hodgkin’s Disease

Summary: The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will comprise of patients who have relapsed or did not respond to treatment and are not eligible for stem cell transplant

Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
- Participants must have a pathologic diagnosis of classical Hodgkin Lymphoma (cHL) who are relapsed or refractory with one of the following:
  - Autologous stem cell transplant (ASCT) ineligible patients
  - Patients after failure of ASCT
- Must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan.

Key Exclusion Criteria:
- Known central nervous system lymphoma.
- Participants with nodular lymphocyte-predominant Hodgkin Lymphoma (HL).
- Participants with known history of pancreatitis or Progressive Multifocal leukoencephalopathy (PML).

Contacts:
- Principal Investigator: Ambuga Badari, MD
- Research Nurses (RN): Elise Curry (elisemarie.curry@ochsner.org, ext. 28084)
  Stephanie Green (stephanie.green2@ochsner.org, ext. 23918)

For additional information: https://clinicaltrials.gov/ct2/show/NCT03138499